EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis

Soon Kyu Lee iD, Jung Hyun Kwon iD, Sung Won Lee iD, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim iD, Do Seon Song, U Im Chang, Jin Mo Yang, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song iD und 13 weitere

Cancers · 04.09.2023 · 15 (17) · 4423

DOI: 10.3390/cancers15174423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 04.09.2023. Verfasst von Soon Kyu Lee und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to compare the treatment outcomes of atezolizumab-plus-bevacizumab (Ate/Bev) therapy with those of transarterial chemoembolization plus radiotherapy (TACE + RT) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) and without metastasis. Between June 2016 and October 2022, we consecutively enrolled 855 HCC patients with PVTT. After excluding 758 patients, 97 patients (n = 37 in the Ate/Bev group; n = 60 in the TACE + RT group) were analyzed. The two groups showed no significant differences in baseline characteristics and had similar objective response and disease control rates. However, the Ate/Bev group showed a significantly higher one-year survival rate (p = 0.041) compared to the TACE + RT group, which was constantly displayed in patients with extensive HCC burden. Meanwhile, the clinical outcomes were comparable between the two groups in patients with unilobar intrahepatic HCC. In Cox-regression analysis, Ate/Bev treatment emerged as a significant factor for better one-year survival (p = 0.049). Finally, in propensity-score matching, the Ate/Bev group demonstrated a better one-year survival (p = 0.02) and PFS (p = 0.01) than the TACE + RT group. In conclusion, Ate/Bev treatment demonstrated superior clinical outcomes compared to TACE + RT treatment in HCC patients with PVTT. Meanwhile, in patients with unilobar intrahepatic HCC, TACE + RT could also be considered as an alternative treatment option alongside Ate/Bev therapy.

Schlagwörter

Stichwörter der Autor:innen

hepatocellular carcinomaimmune checkpoint inhibitorsportal vein thrombosisprogression free survivalradiotherapyresponsesurvivaltransarterial chemoembolization

Autor:innen und Institutionen

  • Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

ORCID-Profile: Soon Kyu Lee, Jung Hyun Kwon, Sung Won Lee, Chang Wook Kim, Myeong Jun Song, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Dong Jae Shim, Myungsoo Kim

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Lee, S. K., Kwon, J. H., Lee, S. W., Lee, H. L., Kim, H. Y., Kim, C. W., Song, D. S., Chang, U. I., Yang, J. M., Nam, S. W., Kim, S. H., Song, M. J., Kim, J. H., Lee, A., Yang, H., Bae, S. H., Han, J. W., Nam, H., Sung, P. S., …, & Kim, M. (2023). A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis. Cancers, 15(17), 4423. https://doi.org/10.3390/cancers15174423

Vancouver

Lee SK, Kwon JH, Lee SW, Lee HL, Kim HY, Kim CW, et al. A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis. Cancers. 2023;15(17):4423. doi:10.3390/cancers15174423

BibTeX
@article{Lee2023,
  author = {Lee, Soon Kyu and Kwon, Jung Hyun and Lee, Sung Won and Lee, Hae Lim and Kim, Hee Yeon and Kim, Chang Wook and Song, Do Seon and Chang, U Im and Yang, Jin Mo and Nam, Soon Woo and Kim, Seok-Hwan and Song, Myeong Jun and Kim, Ji Hoon and Lee, Ahlim and Yang, Hyun and Bae, Si Hyun and Han, Ji Won and Nam, Heechul and Sung, Pil Soo and Jang, Jeong Won and Choi, Jong Young and Yoon, Seung Kew and Shim, Dong Jae and Kim, Doyoung and Kim, Myungsoo},
  title = {A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {17},
  pages = {4423},
  doi = {10.3390/cancers15174423}
}
Kostenlos starten →